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Running title: Asthma treatment affects time to pregnancy. 
 
Take Home Message:  
Use of short-acting relievers, but not long-term preventers, is associated with reduced fertility 
in asthmatic women. 
 











Asthma is a common chronic disease affecting the lives of reproductive age women 
and is associated with 8-13% of pregnancies [1]. While maternal asthma has been 
consistently associated with significant perinatal morbidities and mortality [2, 3], impacts on 
fertility are conflicting.  In light of limited and conflicting evidence, the aim of this study was 




Participants were healthy, nulliparous women recruited to the SCOPE (Screening for 
Pregnancy Endpoints) Study between November 2004 and February 2011 in Auckland, New 
Zealand, Adelaide, Australia, Cork, Ireland, and Manchester and London, United Kingdom. 
The SCOPE study is a multicenter prospective cohort study with the primary aim of 
developing screening tests for prediction of preeclampsia, spontaneous preterm birth, and 
small-for-gestational-age neonates. Ethical approval was obtained from local ethics 
committees [New Zealand AKX/02/00/364, Australia REC 1712/5/2008, London, Leeds and 
Manchester 06/MRE01/98 and Cork ECM5 (10) 05/02/08]. All women provided written 
informed consent. Detailed methods have been described previously. [4]  
 Asthma was self-reported and identified according to the question “Have you been 
diagnosed with asthma by a doctor?”. Asthmatic women were further divided by asthma 
symptoms and asthma medications use, then classified as having former asthma (doctor 
diagnosed asthma, no symptoms in previous 12 months and no use of asthma medications), 
or current asthma (doctor diagnosed asthma, symptoms in previous 12 months or use of 
asthma reliever or preventer medications). Women with current asthma were further divided 
according to use of intermittent reliever medications only (i.e. short-acting beta-agonists 




[SABA]), or additional use of reliever medications (i.e. inhaled corticosteroids [ICS] with or 
without long-acting beta-agonist [LABA]). This resulted in three asthmatic subgroups 
(former asthma, SABA, or ICS±LABA).  
 Information was collected on demographics, smoking, family, medical and 
gynecological history, and anthropometry (height and weight). Maternal ethnicity was self-
reported and categorized as Caucasian or Other. The socioeconomic index (SEI) is a measure 
of socioeconomic position according to income and education, corrected for age [5]. The SEI 
was calculated for all women in SCOPE (range 10-90), with higher score indicating higher 
socioeconomic status [6]. Self-reported polycystic ovary syndrome (PCOS) was categorized 
as yes (confirmed by a scan and/or blood test) or no/unsure. Cigarette use in the three months 
pre-pregnancy was coded any versus not smoking. Age at menarche was reported as a 
continuous variable. Information collected from the biological father included age and BMI. 
 Self-reported time to pregnancy (TTP) was defined as duration of sex (in months) 
without contraception before the current pregnancy and collected in the first trimester. 
Subfertility was defined as TTP>12 months. 
Fecundability odds ratios (FOR) and 95% confidence intervals (CIs) were estimated 
using Cox proportional hazards models for discrete-time data. FORs estimate the odds of 
conceiving each cycle, given exposure to asthma, conditional on not being pregnant in the 
previous cycle. FORs<1 denote reduction in fecundability or longer TTP, and FORs>1 
denote shorter TTP. TTP was censored at 13th months. The proportional hazard assumptions 
were checked with Schoenfeld residuals and graphic methods. The association between 
asthma treatment and TTP was evaluated using logistic regression. Analyses were adjusted 
for possible confounders (in footnotes to Table 1). 
Statistical significance was defined as two-sided p-value <0.05. Analyses were 
undertaken using STATA-IC 14 (Stata, College Station, Texas). 






Of 5617 women in the study, 1106 (19.7%) reported doctor-diagnosed asthma. 
Among women with asthma, 656 (11.7%) were identified as current asthmatics, and 450 
(8.0%) were former asthmatics. Compared with non-asthmatics, women with either current or 
former asthma were younger, had higher BMIs, were more likely to smoke and be of 
Caucasian ethnicity, and had lower socioeconomic status. 
Table 1 shows that compared to non-asthmatics, FORs for current asthmatics 
managed with SABAs were 15% lower (95%CI 0.75-0.96), whereas no difference was 
observed for former asthmatics (aFOR 1.00; 95%CI 0.89-1.13) or current asthmatics using 
ICS±LABAs (aFOR 0.98; 95%CI 0.84-1.15). Compared to non-asthmatics, point estimates 
for subfertility were increased among women using SABAs (aOR 1.30; 95%CI 0.93-1.81), 
but not for women with former asthma (aOR 0.89; 95%CI 0.62-1.28) or current asthma and 
using ICS±LABAs (aOR 1.08; 95%CI 0.69-1.71). Additional sensitivity analyses were 
undertaken including women who conceived following use of assisted reproductive 
technologies, but this did not appreciably change any risk estimates (results not shown). 
 
Discussion 
We show that asthma is associated with reduced fertility but the greatest impact is 
among women with current asthma receiving intermittent reliever treatment with SABAs. 
The lack of associations with ICS±LABAs use suggests that preventer medications may play 
a protective role in improving asthma control and reducing associated systemic inflammation, 
which may drive impaired fertility. This is important as women and healthcare professionals 
express concerns regarding the safety of preventer medications such as inhaled 
corticosteroids during pregnancy. These concerns lead to poor adherence and discontinuation 




of asthma medications during pregnancy, with negative impacts on asthma control and 
pregnancy outcomes [7]. Preconception management of asthma is likely important in 
optimizing pregnancy outcomes, especially given 50% of asthma exacerbations occur in the 
first half of pregnancy [8]. 
 
Literature on the relationship between asthma and fertility is sparse and conflicting. 
Population-based pregnancy cohort studies of women with asthma report associations with 
subfertility [9], use of fertility medications [10] and prolonged TTP [11]. Further, asthmatic 
women with unexplained infertility undergoing fertility treatment experience prolonged TTP 
(55.6 versus 32.3 months; HR 0.50: 95% CI 0.34-0.74), compared with non-asthmatics [12]. 
Data on asthma medication use is limited. Compared to non-asthmatics, Gade et al. observed 
increased risks of prolonged TTP among asthmatic women not taking medication (OR 1.79, 
95%CI 1.20-2.66), as well as women using ICS (OR 2.34, 95%CI 1.33-4.13), but not among 
women using any other asthma medications (OR 0.76, 95%CI 0.51-1.15) [11]. However, 
these findings were not adjusted for potential confounders, including socioeconomic status or 
presence of polycystic ovary syndrome, or paternal factors such as age and BMI that could 
influence the observed associations. Further, fertility and asthma medication data were 
collected retrospectively, with a mean age at data collection of 32 years, whereas mean age at 
conception was 25 years [11]. 
 
While the exact mechanisms underpinning our observations remain unclear, others have 
hypothesized that asthma reduces uterine blood supply or increases infiltration of 
inflammatory cells into the decidua (the uterine mucosal layer), which impairs implantation 
[11]. This is supported by a recent study of women with unexplained infertility receiving 




fertility treatment, that reported asthmatic women had reduced vascular endothelial growth 
factor (VEGF; a potent angiogenic factor) compared with non-asthmatic women [13]. 
 
Strengths of this study include the large cohort and number of women with asthma, 
international representativeness, detailed data on reproductive and non-reproductive 
characteristics and inclusion of many possible confounders. Limitations include that asthma 
was self-reported and medication use was reported at 15 weeks’ gestation and assumed to 
reflect the whole periconceptual period. When comparing self-reported asthma in 
questionnaires to a clinical diagnosis of asthma, Toren et al. identified a sensitivity of 68% 
and specificity of 94% [14]. We further strengthened the identification of asthmatics by 
including data on asthma medication use. Absence of data on asthma control and lung 
function during pregnancy means that we could not examine associations according to 
asthma severity. Further, the cohort recruited nulliparous women who were at low risk of 
pregnancy complications. Therefore, generalizability of the findings to multiparous women is 
uncertain. 
 
In conclusion, the management of asthma with SABAs was associated with reduced fertility, 
whereas the management of asthma with ICS with or without LABAs was not. These 
findings support appropriate management of asthma with inhaled corticosteroid preventer 
medications to ensure optimal asthma control. Women with asthma planning pregnancy 
should be encouraged to continue taking their preventer medications. 
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Table 1:  Associations between asthma and asthma medication use with fecundability† and prolonged time to pregnancy (>12 months) 
 
Fecundability Odds Ratio (FOR)† 





Model 1 (95% CI) 
Adjusted FOR 




Model 1 (95% CI) 
Adjusted OR 
Model 2 (95% CI) 
Non-asthmatic 
(n = 4511) 
1 1 1 1 1 1 
Asthmatic (n = 1106)       
 Former (n=450) 1.12 (1.01-1.24) 1.02 (0.92-1.14) 1.00 (0.89-1.13) 0.84 (0.61-1.15) 0.97 (0.70-1.34) 0.89 (0.62-1.28) 
 Current (n=656)       
 SABA Only (n=421) 0.95 (0.85-1.06) 0.85 (0.76-0.95) 0.85 (0.75-0.96) 1.10 (0.82-1.47) 1.26 (0.92-1.73) 1.30 (0.93-1.81) 
 ICS +LABA (n=235) 1.01 (0.87-1.16) 0.93 (0.81-1.08) 0.98 (0.84-1.15) 1.07 (0.72-1.57) 1.20 (0.80-1.79) 1.08 (0.69-1.71) 
Abbreviations: FOR, fecundability odds ratio; CI, confidence interval; Odds Ratio, OR; SABA, short-acting beta-agonist: ICS, inhaled corticosteroid: LABA, long-
acting beta-agonist 
†Fecundability defined as the average per-cycle probability of conception 
Model 1: maternal BMI, maternal age, recruitment site, socioeconomic status, ethnicity (Caucasian/other), polycystic ovary syndrome (yes/no), smoking status 
(yes/no), and age at menarche 
Model 2: model 1 plus paternal BMI, paternal age 
 
